AGM
HBIO icon

Alpine Global Management’s Harvard Bioscience HBIO Stock Holding History

Alpine Global Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2,478
Closed -$71K – 124
2016
Q2 		$71K Buy
+2,478
New +$78.8K 0.03% 149

Other funds holding HBIO

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Alpine Global Management's HBIO Position: Q3 2016 in Review

Alpine Global Management sold out of Harvard Bioscience (HBIO) in Q3 2016, closing a stake of 2,478 shares — an estimated $71K sold.

Alpine Global Management first reported a position in HBIO in Q2 2016 and held it in 1 quarter. The position peaked at $71K in Q2 2016. 69 funds tracked by Wall St. Rank hold HBIO as of Q3 2016.

  • Alpine Global Management reported no remaining Harvard Bioscience position as of Q3 2016 after selling out during the quarter.
  • Alpine Global Management sold 2,478 Harvard Bioscience shares in Q3 2016, an estimated $71K.
  • Alpine Global Management first reported a position in Harvard Bioscience in Q2 2016 and held it in 1 quarter.
  • Alpine Global Management's Harvard Bioscience position peaked at $71K in Q2 2016.
  • 69 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2016.

Based on Alpine Global Management's 13F filing for Q3 2016, filed 15 Nov 2016.